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Naturally acquired immune responses against human cancers often
include CD8 T cells specific for the cancer testis antigen NY-ESO-1.
Here, we studied T cell receptor (TCR) primary structure and
function of 605 HLA-A*0201/NY-ESO-1157–165-specific CD8 T cell
clones derived from five melanoma patients. We show that an
important proportion of tumor-reactive T cells preferentially use
TCR AV3S1/BV8S2 chains, with remarkably conserved CDR3 amino
acid motifs and lengths in both chains. All remaining T cell clones
belong to two additional sets expressing BV1 or BV13 TCRs,
associated with -chains with highly diverse VJ usage, CDR3 amino
acid sequence, and length. Yet, all T cell clonotypes recognize
tumor antigen with similar functional avidity. Two residues, Met-
160 and Trp-161, located in the middle region of the NY-ESO-1157–165
peptide, are critical for recognition by most of the T cell clonotypes.
Collectively, our data show that a large number of  TCRs,
belonging to three distinct sets (AVx/BV1, AV3/BV8, AVx/BV13)
bind pMHC with equal antigen sensitivity and recognize the same
peptide motif. Finally, this in-depth study of recognition of a
self-antigen suggests that in part similar biophysical mechanisms
shape TCR repertoires toward foreign and self-antigens.
antigen recognition  cytolytic T lymphocytes  melanoma 
T cell receptors  tumor immunity
The specificity of CD8 cytolytic T lymphocyte (CTL) re-sponses relies on the interaction of clonotypically distributed
antigen receptors (TCR) on the surface of the effector cell with
small immunogenic peptide fragments displayed at the surface
of a target cell by self-MHC class I molecules (pMHC) (1).
Binding of the heterodimeric -chains of the TCR to the
pMHC complex is a key step leading to T cell activation and cell
killing. The  TCRs bind agonist pMHCs with relatively low
affinity (Kd 1–100 M) through complementary determining
regions (CDR) present on their variable domains (2). The
mature TCR repertoire is shaped by both positive and negative
intrathymic selection, leading to an estimated 2.5 107 different
TCR clonotypes in the human peripheral T cell pool (3). A
relatively small number of CTL precursor cells is normally
selected in response to the antigenic stimulus and comprises cells
bearing several TCRs (10 to 50 clonotypes) differing from
each other yet having the ability to recognize the same pMHC
complex. The recent development and availability of multimer-
ized MHC–peptide complexes combined to TCR spectratyping
with high-throughput DNA sequencing allowed the study of the
development of antigen-driven CD8 T lymphocyte response to
chronic antigenic exposure, e.g., in viral infection (CMV, EBV,
HIV) or in cancer patients. The impact of TCR diversity on
recognition of single antigenic pMHC complexes has been
extensively investigated, and the relative contributions of each
TCR -chain have been addressed in several models. In a few
systems, strong biases in the TCR repertoire selection of antigen-
specific T cells, resulting in the preferential usage of particular
 TCR combinations, have been reported (4, 5) [supporting
information (SI) Text].
Over the last 10 years, 24 class I and class II TCR–pMHC
complexes have been crystallized and identified a substantial
degree of structural variability in TCR–pMHC recognition
(reviewed in ref. 6). In many cases, the TCRV interactions with
the pMHC seem to predominate and, thus provide some basis for
a conserved diagonal orientation of the TCR on the pMHC.
Importantly, all aspects of TCR binding to pMHC have direct
implications for TCR function. For instance, there is a direct link
between peptide–MHC affinity and the efficiency of recognition
by CD8 T lymphocytes (7), as similarly, there is a close
relationship between the Kd of the TCR binding and the activity
of the T cell in cytolytic assays (8, 9). Nevertheless, despite all of
these efforts, the structural bases of TCR repertoire selection for
pMHC complexes remain elusive.
The molecular recognition events taking place at the TCR–
peptide–MHC interface are of great interest for medical appli-
cations. In particular, studies underlying pMHC recognition
have important implications for the design of therapeutic anti-
gen-based vaccines or of engineered TCRs. Therefore, the
analysis of the primary structure of both - and -chains of the
TCR, especially when combined with the functional analysis of
the corresponding clonal populations of T cells, can provide
important insights in TCR repertoire selection in response to a
given pMHC ligand (10). Here, we report a detailed and
combined molecular and functional characterization of the TCR
repertoire specific for the cancer testis (CT) antigen NY-ESO-
1157–165 bound to HLA-A*0201, by the analysis of large numbers
of T cell clones and TCRs derived from melanoma patients with
naturally occurring CD8 T cell responses.
Results
Naturally Occurring NY-ESO-1157–165-Specific CD8 T Cell Responses
Display a Preferential Usage of BV1, BV8, and BV13 TCRs. Previous
studies have focused much attention on tumor antigens encoded
by cancer germ-line genes, whose expression can be found in
various types of tumors but not in normal adult tissues, with the
exception of testis. In particular, because of its frequent expres-
sion in tumors and immunogenicity in advanced cancer patients,
NY-ESO-1 is currently viewed as an ideal candidate for thera-
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peutic tumor antigen-based vaccines. Recently, we reported an
unusually strong natural tumor-specific immune response
against NY-ESO-1157–165 in patient LAU 50 with advanced
melanoma (11), characterized by expansions of codominant T
cell clonotypes bearing distinct BV1, BV8, or BV13 TCRs (12).
These data prompted us to examine the proportion of BV1, BV8,
and BV13 TCRs present within NY-ESO-1-specific T cells of
peptide-stimulated PBMCs from four additional melanoma pa-
tients with naturally occurring NY-ESO-1-specific CTL re-
sponses (13). By using HLA-A2/NY-ESO-1157–165 multimers in
combination with mAbs directed against the variable region of
TCR BV1, BV8, and BV13, we found that the majority of
multimer T cells expressed TCRs with these BV elements (Fig.
S1), in line with a recent report by Le Gal and colleagues (10).
Restricted CDR3 Diversity and High Sequence Homology Among
NY-ESO-1-Specific TCRs Bearing the TCR BV8 Gene Segment.Using an
approach that combines flow cytometry based-cell sorting, TCR
spectratyping, and sequencing at the single cell level, we recently
identified, in a single patient (LAU 50), nine codominant
NY-ESO-1-specific T cell clonotypes characterized by distinct
BV1, BV8, or BV13 TCRs sequences (12). Extensive studies of
their clonal composition revealed a high degree of sequence
homology of the NY-ESO-1-specific TCRs bearing the TCR
BV8 gene segment (Fig. S2). These data prompted us to examine
in great detail 605 NY-ESO-1-specific T cell clones generated in
vitro from patients LAU 50, LAU 97, LAU 155, LAU 156, and
LAU 198 (Fig. S1). Complete TCR analysis by sequencing
allowed the identification of a total of 49 NY-ESO-1-specific
clonotypes, classified into BV1 (12 times), BV8 (21 times), or
BV13 (16 times) TCR usage (Fig. 1), including the nine char-
acterized clonotypes from patient LAU 50 (12). A striking
feature was that, with two exceptions, all BV8-expressing NY-
ESO-1-specific clonotypes shared the same relatively short
length of the -chain CDR3 region (7 aa). Moreover, there was
a preferential usage of either the BJ1S1 or the BJ2S1 gene
segments and a marked conservation of the CDR3 amino acid
composition, particularly at positions 3, 6, and 7 with prominent
usage of a glycine, a glutamate, and a glutamine residue,
respectively. Interestingly, the TCR analysis of BV1- and BV13-
specific T cell clones yielded different results. Indeed, despite
conserved BV usage, most of these clonotypes used different BJs
and different CDR3 loop sequences of highly variable lengths
ranging from 6 to 13 aa (Fig. 1).
BV8 T Cell Clonotypes Pair with a Highly Restricted Set of V-Chains
in Contrast to the BV1 and BV13 NY-ESO-1-Specific T Cell Clonotypes.
To assess the full extent of conservation of the primary TCR
structure of the BV8 T cell clonotypes, we next examined the
TCR -chain clonal diversity and junctional features of the 20
NY-ESO-1-specific T cell clones defined as dominant clonotypes
based on their frequencies, implying that at least three individual
T cell clones share the identical TCR -chain sequence (Fig. 1).
Strikingly, sequencing of the complementary TCR -chains
demonstrated the highly recurrent usage of the AV3S1 gene
segment by all BV8S2 T cell clonotypes (Fig. 2). Moreover, we
observed a marked conservation of the V(D)J junctional se-
quences and a unique CDR3 length (6 aa) within clonotypes
derived from the same and distinct patients. Aside the prefer-
ential usage of the AJ31 gene segment, the dominant NY-ESO-
1-specific T cell clonotypes were also characterized by their
preferred selection of aspartate/leucine at CDR3 positions 1/6,
respectively. In sharp contrast, the V repertoires associated
with both BV1 and BV13 TCRs were highly heterogeneous and
comprised various AJs and various CDR3 lengths ranging from
7 to 14 aa (Fig. 2).
Similar Efficient Tumor Cell Recognition and Killing by NY-ESO-1-
Specific T Cell Clones with Distinct Primary TCR Structures. To
evaluate the relationship between the NY-ESO-1-specific T
cell clonotypes and functional avidity for antigen recognition,
82 T cell clones generated from patient LAU 50, distributed
according to their TCR BV1, BV8, or BV13 clonotypic
expression, were assessed in chromium release assays for their
ability to recognize graded concentrations of the native NY-
ESO-1157–165 peptide pulsed to T2 cells (Fig. 3). Remarkably,
Patient BV CDR3 BJ # clones
1 2 3 4 5 6 7 8 9 10 11 12 13
LAU 50 BV1 T S S G A N V L 2S6 1
1 LAU 50 BV1S1 S V T G T G G G 2S1 61
2 LAU 50 BV1S1 S V T G T E E A 1S1 6
3 LAU 50 BV1S1 S V D G S N Q P Q 1S5 10
4 LAU 155 BV1S1 S V A T G G D T Q 2S3 29
LAU 50 BV1 S V P G D T D T Q 2S3 1
LAU 50 BV1 S L A H L G E T Q 2S5 1
5 LAU 155 BV1S1 S L A T G G D T Q 2S3 5
LAU 50 BV1S1 S P T Q E G Y S P L 1S6 2
LAU 50 BV1S1 S P E E G R T D T Q 2S3 2
LAU 50 BV1 S V A G D I Q E T Q 2S5 1
LAU 50 BV1 S S Q G G G G T R Q 2S7 1
LAU 50 BV8S2 S R T G E V 2S7 2
LAU 50 BV8 S F R Q E T Q 2S5 1
LAU 97 BV8 S F H T D T Q 2S3 1
LAU 155 BV8 S Q G A N V L 2S6 1
LAU 155 BV8 S L G A G E A 1S1 1
6 LAU 50 BV8S2 S L G G T E A 1S1 29
7 LAU 50 BV8S2 S L G G N E Q 2S1 9
8 LAU 155 BV8S2 S L G S T E A 1S1 20
LAU 97 BV8 L L A A G E L 2S2 1
9 LAU 50 BV8S2 Q Q G G T E A 1S1 96
10 LAU 50 BV8S2 K Q G G N E Q 2S1 4
11 LAU 156 BV8S2 K G G A N E Q 2S1 31
LAU 50 BV8 K P G A G E Q 2S7 1
12 LAU 155 BV8S2 N S G A N E Q 2S1 3
13 LAU 155 BV8S2 N S G S N E Q 2S1 11
LAU 50 BV8 N Q G A Q P Q 1S5 1
LAU 155 BV8 N T G A N E Q 2S1 1
LAU 155 BV8 R K G P N E Q 2S1 1
LAU 50 BV8 R P A G Q P Q 1S5 1
LAU 50 BV8 R V G A D T Q 2S3 1
LAU 50 BV8 S L D R A T N E K L 1S4 1
14 LAU 155 BV13S1 L K G L T Q 2S5 7
15 LAU 50 BV13S1 R T G L D G Y 1S2 135
LAU 50 BV13 A P R E N Y G Y 1S2 1
LAU 50 BV13 S P T G F N E Q 2S1 1
LAU 50 BV13 S Y S G V Q E T Q 2S5 1
16 LAU 155 BV13S1 S Y V G A A G E L 2S2 6
LAU 50 BV13 S Y R G G S E T Q 2S5 1
17 LAU 50 BV13S1 S Y V G G K A E A 1S1 77
18 LAU 198 BV13S1 S Y E A G A E T Q 2S5 21
LAU 50 BV13 S S K L V G E T Q 2S5 1
LAU 50 BV13 R D R Q A N Y E Q 2S7 1
19 LAU 50 BV13S6 S L T G H Y N S P L 1S6 6
20 LAU 155 BV13S6 S L T G G L N S P L 1S6 5
LAU 155 BV13 S Y Q G G G K N T E A 1S1 1
LAU 155 BV13S6 L G D G D G A Y N S P L 1S6 2
LAU 156 BV13S2 S R D S A L W I S T D T Q 2S3 2
Fig. 1. Sequence analysis of TCR junctional transcripts derived from BV1,
BV8, and BV13NY-ESO-1157–165 multimer T cell clones from five melanoma
patients. Transcripts were reverse-transcribed and amplified from multimer
T cell clones by using either pairs of BV1/BC, BV8/BC, or BV13/BC primers. PCR
products were directly purified and sequenced. Conserved residues forming
the CDR3 loop and preferential BJ gene element usages are highlighted in
gray. The number of in vitro generated T cell clones displaying a given
sequence is depicted. Of note, the NY-ESO-1-specific CD8 T cell response seen
in patients LAU 156 and LAU 198 was composed of, respectively, a single
dominant BV8 and BV13 T cell clonotype, confirming the results obtained by
using anti-BV antibodies and flow cytometry (Fig. S1).
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most of the BV1-, BV8-, and BV13-derived clonotypes showed
similar functional avidity because 50% maximal lysis of T2
cells was found at similar peptide doses (109/1010 M). One
exception was BV13 clonotype 2 that exhibited a slightly but
statistically significant inferior functional avidity of antigen
recognition compared with the other tested clonotypes. Lysis
of targets sensitized with an analog peptide with a C to A
substitution at peptide position 9 was achieved at 1 log lower
peptide concentrations (1010/1011 M), which corresponds to
the increased pMHC stability (14). The ability of the BV1,
BV8, and BV13 clonotypes to specifically lyse NY-ESO-1-
expressing tumor cell lines revealed that all distinct T cell
clonotypes efficiently and similarly recognized the NY-ESO-
1-expressing melanoma cell lines Me 275 and Me 290 (Figs. S3
and S4). Altogether, our results demonstrate that T cells
bearing three distinct sets of  TCRs (AVx/BV1S1, AV3S1/
BV8S2, or AVx/BV13) shared similar avidity for antigen
recognition and tumor reactivity, irrespective of their BV
usage.
Both Met and Trp Residues Located in the Middle Region of the
Antigenic Peptide Are Critical TCR Contact Residues Regardless of TCR
Gene Segment Usage. To gain information about the specific role of
each single amino acid of the NY-ESO-1 peptide in the interaction
with well defined TCRs, we analyzed the cytotoxicity of 11 BV1,
BV8, and BV13 molecularly defined T cell clonotypes against T2
cells loaded with a set of NY-ESO-1157–165 single alanine-
substituted peptide variants. The recognition patterns of each
codominant clonotype are depicted in Fig. 4A. The relative anti-
genic activity was calculated by using the native peptide NY-ESO-
1157–165 as reference. As described (13, 14), the peptide with the
C165A replacement appeared to be the most efficient antigenic
peptide analog, improving HLA-A2 binding and resulting in a
marked increase in the recognition by every clonotype. All four
BV8 clonotypes exhibited a more homogeneous pattern of fine
specificity of recognition compared with the recognition patterns
found for BV1 and BV13 T cell clones. Strikingly, several amino
acid residues located in the middle region of the antigenic peptide
(P3–P8) appeared critical for the recognition by BV1, BV8, or
Clonotype ID BV CDR3 BJ AV CDR3 AJ
1 2 3 4 5 6 7 8 9 10 11 12 13 1 2 3 4 5 6 7 8 9 10 11 12 13 14
1 LAU 50-clono1 BV1S1 S V T G T G G G 2S1 AV25S1 Y M D S N Y Q L 33
2 LAU 50-clono3 BV1S1 S V T G T E E A 1S1 AV6S1 P Y S F S G G Y N K L 4
3 LAU 50-clono2 BV1S1 S V D G S N Q P Q 1S5 AV4S1 R K T S Y D K V 50
4 LAU 155-clono1 BV1S1 S V A T G G D T Q 2S3 AV2S1 P Y S G A G S Y Q L 28
5 LAU 155-clono2 BV1S1 S L A T G G D T Q 2S3 AV2S1 N K A S G N T P L 29
6 LAU 50-clono2 BV8S2 S L G G T E A 1S1 AV3S1 D A E A R L 31
7 LAU 50-clono3 BV8S2 S L G G N E Q 2S1 AV3S1 D G E S R L 58
8 LAU 155-clono2 BV8S2 S L G S T E A 1S1 AV3S1 D G D A R L 31
9 LAU 50-clono1 BV8S2 Q Q G G T E A 1S1 AV3S1 D K N A R L 31
10 LAU 50-clono4 BV8S2 K Q G G N E Q 2S1 AV3S1 D G V G K L 23
11 LAU 156-clono1 BV8S2 K G G A N E Q 2S1 AV3S1 D E S A R L 31
12 LAU 155-clono3 BV8S2 N S G A N E Q 2S1 AV3S1 D G N A R L 31
13 LAU 155-clono1 BV8S2 N S G S N E Q 2S1 AV3S1 D E W G K L 23
14 LAU 155-clono2 BV13S1 L K G L T Q 2S5 AV3S1 D A S Y G Q N F 26
15 LAU 50-clono1 BV13S1 R T G L D G Y 1S2 AV14S1 S D S N Y Q L 33
16 LAU 155-clono1 BV13S1 S Y V G A A G E L 2S2 AV23S1 R P Q T G G S Y I P 6
17 LAU 50-clono2 BV13S1 S Y V G G K A E A 1S1 AV23S1 R S S M D S N Y Q L 33
18 LAU 198-clono1 BV13S1 S Y E A G A E T Q 2S5 AV6S2 R E G P S G G G T S Y G K L 52
19 LAU 50-clono3 BV13S6 S L T G H Y N S P L 1S6 AV2S1 G G G A N N L 36
20 LAU 155-clono3 BV13S6 S L T G G L N S P L 1S6 AV7S2 T V D S N Y Q L 33
*
*
*
*
*
*
*
Fig. 2. Junctional amino acid sequence of TCR -chains associated with each TCR  transcript derived from dominant NY-ESO-1157–165-specific T cell clonotypes.
Conserved residues forming the CDR3/ loops and preferential AJ/BJ gene element usages are highlighted in gray. *, Clonotypes recently described in ref. 10.
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BV13 T cell clonotypes. Bothmethionine (P4) and tryptophan (P5)
residueswere particularly crucial for their interactionwith theTCR,
as demonstrated by the low recognition by all of the BV1, BV8, and
BV13 clonotypes for the peptides containing M160A and W161A
substitutions (Fig. 4A). Finally, other residues (Leu-P3, Ile-P6,
Thr-P7, andGln-P8) were highly critical for only some but not other
clonotypes (either BV1, BV8, or BV13). The contributions of the
side chains of theNY-ESO157–165 peptide to the binding free energy
of the BV13 clonotype 1 from patient LAU 155 were calculated
according to the Molecular Mechanics–Generalized Born Surface
Area (MM-GBSA) approach (Fig. 4B and SI Text) and are in good
agreement with the functional recognition pattern found for the
same clonotype (Fig. 4A). This particular clonotype was chosen
because of the availability of a very closely related TCR–pMHC
x-ray structure, designated as the 2BNR complex (15).
Prevalent Contribution of the TCR -Chain for the Binding Free Energy
Toward the NY-ESO-1157–165/HLA-A*0201 Complex. The in silicomod-
eling of the TCR–pMHC was performed for the 20 dominant
NY-ESO-1-specific T cell clonotypes. For each model and for
the 2BNR structure (15), we calculated side chains and backbone
contributions to the binding free energy made by the TCR
residues (SI Text). Fig. 4C shows a histogram count of the
models, as a function of the G,bind  G,bind difference.
Except for BV1-clono2 (LAU 155) TCR, a large majority of
models showed a preferential -chain contribution (i.e., a neg-
ative G,bind  G,bind difference), revealing its greater im-
portance compared with the -chain, in the binding with NY-
ESO peptide and MHC complex.
Discussion
In the present work, we performed a detailed analysis of primary
structure and function of the TCR  repertoire toward the
immunodominant HLA-A2/NY-ESO-1157–165 epitope. The anal-
ysis of a large number of T cell clones (605 clones) showed that
an important proportion of tumor-reactive CD8 T lymphocytes
preferentially expressed the TCR AV3S1-BV8S2 chains with a
remarkably high degree of conservation of CDR3 and 
domains, in terms of both length and amino acid composition at
certain positions. These data are further emphasized by the
comparable recognition patterns of fine specificity exhibited by
distinct AV3/BV8 T cell clonotypes, as revealed by the experi-
ments using a set of single alanine-substituted NY-ESO-1 pep-
tides. Collectively, this report demonstrates that similarly to the
CD8 T cell responses observed against viral influenza A matrix
protein and EBV EBNA3 epitopes (4, 5), highly restricted and
conserved TCR  usage can also be observed in CTL responses
toward self/tumor antigens such as NY-ESO-1.
Another major finding is that besides the selected AV3S1/
BV8S2 set of T lymphocytes, NY-ESO-1-specific TCR reper-
toires were biased toward the usage of BV1 and BV13 gene
segments. However, in contrast to the AV3S1/BV8S2 set, the
BV1 and BV13 TCR sets revealed corresponding V repertoires
of high diversity. Overall, these TCR -chains were character-
ized by different V and J usage of highly variable CDR3 length
and amino acid composition. Similar to our data, a recent study
showed that CTL specific for the protective immunodominant
nucleoprotein epitope (NP366–374) of influenza A viruses in B6
mice used a highly restricted V repertoire but no conserved V
of the binding free energy contributions made by the TCR V residues and the
TCR V residues toward the HLA-A*0201/NY-ESO-1157–165 complex. Histogram
count of 19 of the 20 TCR models was generated in silico, as a function of the
G,bind G,bind difference. The G,bind G,bind difference is in kilocalo-
ries per mole. Of note, the 2BNR (15) G,bind  G,bind difference was 6.4
kcal/mol, conferring again a preponderant role to the -chain in the binding
process.
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Fig. 4. Contribution of individual NY-ESO-1157–165 amino acid residues to
functional antigen recognition by specific T cell clonotypes. (A) The relative
antigenicity of alanine-substituted NY-ESO-1 peptide analogs was assessed on
T2 target cells in the presence of graded peptide concentration. We used five
and six distinct T cell clonotypes (BV1, BV8, and BV13) isolated from patients
LAU 155 and LAU 50, respectively. The molar concentration required for 50%
maximal lysis by each T cell clone and for each peptide was calculated from
peptide titration experiments. The relative antigenic activity of each peptide
analog was determined by using the native peptide NY-ESO-1 as a reference
(SI Text). The recognition patterns of BV1-, BV8-, and BV13-derived clonotypes
are depicted in separate panels of graphs. (B) Estimation of the binding free
energy contributions of each residue of the NY-ESO-1157–165 peptide for the
TCR BV13 clonotype 1 isolated from patient LAU 155. Of note, the side chains
of the central residues (P4–P8) showed important favorable contributions in
the binding between peptide and TCR, whereas the contributions of the outer
side chains (P1, P2, P3, and P9) were not significant. (C) Comparison of the sum
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repertoire (16). Despite the limited set of human T cell clones
analyzed, similar conclusions were reached by another study
based on HIV-specific CTL responses from long-term survivors
(17). Altogether, these observations reveal an unsuspected di-
versification of the TCR  repertoire, which would have been
qualified as ‘‘highly restricted’’ had such analyses remained
limited to the TCR -chain repertoire. Therefore, TCR reper-
toire studies need to include the characterization of both TCR
- and -chains and not only the latter as done in the majority
of previous studies.
Because NY-ESO-1-specific T cells expressed biased TCR
BV1 and BV13 chains but can use a variety of TCR -chains, our
data suggest that recognition of the NY-ESO-1157–165/HLA-
A*0201 complex may predominantly depend on the TCR
-chain. In this regard, the in silico modeling of the NY-ESO-
1-specific T cell repertoire combined with the MM-GBSA
decomposition of the binding free energy into TCR  and 
contributions revealed that a large majority of specific T cell
clonotypes have a preferential -chain contribution to the
TCR–pMHC binding compared with their corresponding
-chain. Collectively, our finding emphasizes the prevalent role
of the -chain in contributing tomore favorable interactions with
the pMHC ligand than the -chain. Curiously, the results
described here and in the above-mentioned studies do not exactly
recapitulate those found by others that rather suggest a predom-
inant role of TCR -chain in determining the preimmune
repertoire of antigen-specific T cells (18–20). In line with this
view, Yokosuka et al. (18) have investigated the potential
spectrum of TCR -chains to exhibit antigen specificity by
systematically analyzing hundreds of individual TCR  pairs for
antigen-specific recognition. Their findings show that to recog-
nize the HIVgp160 peptide/H-2Dd complex, CTLs have to
possess a single TCR -chain but can use a variety of TCR
-chains. Restricted -chain usage (i.e., V2.1) was also found
among HLA-A2/Melan-A specific T cells (19, 20). Consistent
with these results, Miles et al. (21) have recently shown thatMHC
restriction in the CD8 T cell response to an epitope from EBV,
which is naturally immunogenic across two human MHC class I
alleles, can be controlled exclusively by TCR -chain usage.
Many self-antigens are expressed in the thymus (22), associ-
ated with negative selection of T cells expressing specific TCRs,
in some instances explaining why self/tumor antigen-specific
TCRs are of lower avidity as opposed to pathogen-specific TCRs
(2). For example, the self/tumor antigen Melan-A/MART-1 is
recognized by relatively low avidity TCRs, and these TCRs
present higher degrees of TCR -chain heterogeneity (23).
Although avidities of the HLA-A2/NY-ESO-1 specific TCRs are
somewhat higher, they still do not reach the high avidities
observed among virus-specific TCRs. Nevertheless, the majority
of HLA-A2 individuals are capable of mounting vigorous CD8
T cell responses to this antigen, confirming that it is a prefer-
ential target of tumor-specific T cells. Thus, one could speculate
that the TCR repertoire studied here is not (much) impaired by
thymic negative selection. The question remains open whether
similar observations as shown here for NY-ESO-1-specific TCRs
can be made for TCRs specific for other self/tumor antigens.
What remains intriguing, at present, is which biophysical
mechanisms allow TCRs that either display highly conserved
V- and -chains or semiconserved V-chains pairing with
complementary diverse V-chains, to recognize the same
pMHC complex. Despite the 24 solved structures of TCRs–
pMHC complexes (6), many of the structural principles that
govern MHC restriction still remain unclear. The crystal of the
influenza MP58–66/HLA-A2-specific TCR AV10S2/BV17 pro-
vides some structural explanations for the specific contribution
of BV17 (24). Indeed, the distinctive orientation of this TCR,
which is almost orthogonal to the peptide-binding groove of
HLA-A2, facilitates insertion of a conserved arginine in the V
CDR3 into a notch between the bound peptide and the MHC
2-helix. This unusual interaction may compensate for the lack
of prominent side chains of the Flu-peptide pointing toward the
TCR (25). Further insights in the comparison of reported
TCR–pMHC crystal structures reveal that TCR binding gener-
ally occurs in a flexible diagonal orientation to the long axis of
the MHC peptide-binding groove (6). Class I MHC molecules
usually bind peptides of 8–10 residues in length (on average 9
mers defined as P1–P9) in an extended conformation in which
the peptide is fixed at its ends by pockets formed by the MHC
molecule. In contrast, the centrally located peptide residues
exhibit upward-pointing amino acid side chains that often inter-
act directly with TCR CDR3 loops (6).
Because the NY-ESO-1/A2 complex preferentially selects and
binds to (i) conserved AV3S1/BV8S2 and (ii) semiconserved
AVx/BV1 and AVx/BV13 TCRs, this antigenic model provides
us with the unique opportunity to examine in detail the bio-
physical nature of distinct TCRs recognizing the same pMHC
ligand and the impact of each TCR - and -chain on such
recognition. Our functional data, using a panel of NY-ESO-
1157–165 single alanine-substituted peptide variants, revealed the
critical role played by two central residues, Met-P4 and Trp-P5,
for the antigenic recognition by different T cell clonotypes. The
work reported here confirms and further extends the results
obtained from the crystal structure of the 2BNR complex,
indicating that binding of the TCR centers on two prominent side
chains of the two central amino acids, methionine–tryptophan
(15), forming a predominant hot spot interacting with the
CDR3 and  loops (26). Because our observations were made
on an extended pool of dominant T cell clonotypes isolated from
two different patients (LAU 50 and LAU 155), they indicate that
this represents a general feature, i.e., that distinct TCRs (AVx/
BV1, AV3S1/BV8S2, AVx/BV13) share comparable peptide
recognition patterns, suggesting conserved binding modes of
distinct A2/NY-ESO-1 specific TCRs. In particular, preliminary
observations on in silico models suggest that some conforma-
tional motifs within the CDR3 loop may be critical for the
binding to the NY-ESO-1157–165 peptide (data not shown). The
issue of which residues within the CDR1, CDR2, and CDR3 
and  loops present dominant contributions to (i) antigen
recognition and (ii) MHC recognition deserves additional stud-
ies combining detailed structural and functional investigations.
A better understanding of structural principles that govern
TCR recognition is essential to promote research and clinical
applications. The quality of TCRs recruited during disease, or by
vaccination, dominantly influences the potency of immune re-
sponses (27). To improve therapeutic immune interventions,
TCRs need to be fully characterized, and the mechanisms for
their recruitment and function must be elucidated. Results from
such studies impact, e.g., on the design of antigens for vaccina-
tion and on the choice of optimal TCRs for adoptive T cell
therapy, with or without TCR gene transfer. Here, we show that
the TCR -chain, comparable with the TCR -chain in other
models, may play an important role in the recognition of pMHC
complexes and that depending on the pMHC model, each chain
may present dominant contributions to antigen recognition. In
addition, similar mechanisms may control TCR repertoire shap-
ing toward foreign or self-antigens because the predominant
contribution of the TCR - or -chain can be observed under
various physiopathological contexts, e.g., acute or chronic in vivo
triggering by either viral or tumor antigens. Finally, our data
demonstrate that three distinct sets of TCRs (AVx/BV1, AV3/
BV8, and AVx/BV13) are able to recognize the same NY-ESO-
1/MHC complex with comparable and high functional avidity,
conferring successful tumor recognition.
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Materials and Methods
Patients, Cell Preparation, and Flow Cytometry. Five HLA-A*0201 melanoma
patients (LAU 50, LAU 97, LAU 155, LAU 156, and LAU 198) provided written
informed consent and thus participated in this study of the Ludwig Institute
for Cancer Research (LICR) and of the Multidisciplinary Oncology Center,
which was approved by Institutional Review Boards and the LICR Protocol
Review Committee. Samples were collected and processed for peptide stim-
ulation experiments and for HLA-A2/peptide multimer staining as described in
the SI Text.
Generation of T Cell Clones and Functional Cytolytic Assays. Multimerpos CD8pos
T cells were sorted in a FACSVantage SE machine (Becton Dickinson) and
cloned by limiting dilution and expanded as described in the SI Text. The
functional avidity of antigen recognition was analyzed for in vitro generated
T cell clones, isolated from patients LAU 50 and LAU 155, and bearing molec-
ularly defined  TCR clonotypes as detailed in the SI Text.
TCR-BV and -AV Repertoire Analysis. TCR-BV and -AV repertoire analysis was
performed after spectratyping, sequencing, and clonotyping as detailed in the
SI Text.
Binding Free Energy Calculations. The estimation of the binding free energy
contributions of each residue of the NY-ESO-1 peptide to the TCR–pMHC
association was performed on the TCR BV13 clonotype 1 from LAU 155, which
is highly related to the TCR AV23-BV13 (1G4) bound to NY-ESO-1157–165/HLA-
A*0201 (15), as described in the SI Text.
Computational TCR Modeling. To calculate the binding free energy contribu-
tions made by the TCR V and V residues, homology models of the variable
domain of the TCR bound to the SLLMWITQC peptide presented by HLA-
A*0201 were built by using Modeler 6v2 (28), based on the 2BNR complex (15)
and other crystal structures of TCR from the Protein Data Bank (SI Text).
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In a few systems, strong biases in the T cell receptor (TCR)
repertoire selection of antigen-specific T cells, resulting in the
preferential usage of particular  TCR combinations, have
been reported (1–3). The human CTL response to influenza A
matrix in individuals with HLA-A*0201 is characterized by
prominent usage of the TCR-AV10.2-BV17 containing a con-
served Arg–Ser–Ser sequence within the CDR3 regions (1, 3).
Another example involves the T cell response to the EBNA3
antigen of Epstein–Barr virus (EBV) seen in HLA-B8-positive
individuals whereby nearly all specific CD8 T cells use TCR-
AV4.1-BV6.2 and share conserved CDR3 sequences (2). More
recently, Gillespie et al. (4) described the preferential usage of
AV15.1 and BV17 TCR, with striking sequence conservation
throughout the hypervariable region, in a HLA-B*57-restricted
immune response in HIV-1 infection.
Results. Naturally occurring NY-ESO-1157–165-specific CD8 T cell re-
sponses display a preferential usage of BV1, BV8, and BV13TCRs.By using
HLA-A2/NY-ESO-1157–165 multimers in combination withmAbs
directed against the variable region of TCR BV1, BV8, and
BV13, we found that the majority of multimer T cells expressed
TCRs with these BV elements Fig. S1, in line with a recent report
by Le Gal et al. (5). In patients LAU 50, LAU 155, LAU 156, and
LAU 198, the proportion of NY-ESO-1-specific T cells bearing
TCR BV1 was lower compared with cells expressing TCR BV8
and/or BV13 segments. BV8-positive cells were found predom-
inantly in patient LAU 156, whereas most of the tumor-specific
T cells of patient LAU 198 displayed the BV13 segment.
Analysis of distinct TCR BV1, BV8, and BV13 NY-ESO-1-reactive T cells by
using clonotypic primers. The TCR BV and AV nomenclature used
was according to Arden et al. (6) and Genevee et al. (7). To study
the clonal composition of NY-ESO-1-specific T cell clones
generated from patient LAU 50 (8), two distinct sets of primers
specific for each clonotypic CDR3 sequence of these character-
ized T cell clones were designed: forward (Fwd) and reverse
(Rev) (Fig. S2A). The sets designed for BV1 and BV13 T cell
clonotypes were highly specific and allowed efficient clonotypic
discrimination of each respective clone (Fig. S2 B and D). In
contrast, all designed BV8 clonotypic primers displayed some
degree of cross-reactivity among clonotypes 1–4 (Fig. S2C). In
addition, BV8 clonotype-specific PCRs were clearly less efficient
in identifying the different clonotypes because a large fraction of
the performed PCRs (44%) gave a single positive product (/
instead of /), and full clonotypic discrimination required
extensive sequencing (Fig. S2E). Consistent with these results,
sequence alignment and comparison of the four BV8 NY-ESO-
1-specific T cell clonotypes revealed a high degree of homology
in both the length and sequence of the CDR3 region (Fig. S2B
and ref. 8).
Assessment of tumor cell killing by NY-ESO-1-specific T cell clones from
patient LAU 50. Overall, all distinct T cell clonotypes efficiently
recognized the NY-ESO-1 expressing melanoma cell lines Me
275 and Me 290, the former of which was autologous (i.e.,
derived from a metastasis of patient LAU 50). Consistent with
the data obtained from peptide-pulsed T2 cells (see Fig. 3 of the
main text), BV13-clono2 cells recognized tumor cells slightly less
efficiently (Fig. S3).
Distinct NY-ESO-1-specific T cell clonotypes from patient LAU 155 exhibit
similar functional avidity of antigen recognition. We compared the
efficiency of peptide recognition by NY-ESO-1-specific T cell
clonotypes isolated from another melanoma patient, LAU 155,
by peptide titration killing assays on 17 representative T cell
clones of defined TCR clonotypic sequences (Fig. S4). Most
BV1-, BV8-, and BV13-derived clones killed T2 cells with an IC50
ranging widely between 1010 and 108 M for the native and 2
1011 and 109 M for the analog peptide, respectively. BV13
clonotypes displayed slightly superior peptide recognition com-
pared with BV1 and BV8 clones, in line with their increased
ability to recognized NY-ESO-1-expressing tumor cell lines (Me
275, Me 290) (data not shown). Altogether, these data further
support the notion that T cells bearing three distinct sets of TCRs
(either AVx/BV1, AV3/BV8, or AVx/BV13) shared similar
avidity for antigen recognition, irrespectively of their BV usage.
Discussion. An important aspect is the functional antigen recog-
nition and its relation to TCR sequence and structure. Our work
was focused on dominant T cell clonotypes, which had expanded
successfully in vivo. Therefore, it was particularly interesting to
investigate whether their TCRs conferred efficient antigen rec-
ognition also in vitro, justifying the effort to generate a very large
number of functional T cell clones. Indeed, they recognized and
killed NY-ESO-1 tumor cells and peptide-pulsed T2 cells
efficiently and with similar functional avidity, despite the usage
of largely different TCRs. These data are consistent with our
recent report (8) showing that in patient LAU 50, both BV8 and
BV13 tumor-reactive clonotypes efficiently secreted effector
mediators such as granzyme B, perforin, and IFN-, and killed
tumor cells when tested directly ex vivo in a LiveCount assay (9).
Altogether, these observations revealed that T cell clonotypes
bearing molecularly defined distinct TCRs not only displayed full
effector function but also killed target cells with similar antigen
sensitivity, indicating that different TCR  usage was not
associated with different functional TCR avidity.
Another finding was that despite the relative diversification of
the NY-ESO-1-specific TCR repertoire with the characteriza-
tion of up to 12, 21, and 16 distinct BV1, BV8, and BV13 V(D)J
junctional sequences, respectively (see Fig. 1 in the main text),
the number of dominant NY-ESO-1-specific T cell clones found
among individual melanoma patients was in fact rather limited.
In patients LAU 50 and LAU 155, we, respectively, identified 10
and 6 distinct and codominant T cell clonotypes bearing BV1,
BV8, and BV13 TCRs. Strikingly, we recently reported that the
great majority of NY-ESO-1-specific T lymphocytes, in patient
LAU 50, were composed of BV8 clonotypes 1 and 2 and of BV13
clonotypes 1 and 2 (8). Finally, NY-ESO-1/A*0201-specific T cell
responses were dominated by a single dominant clone in patients
LAU 156 and LAU 198, respectively. Collectively, our data
indicate that similarly to our study on T cell responses against the
immunodominant Melan-A/MART1 antigen (10), responses to
NY-ESO-1 are also caused by selection and amplification of
particular T cell clonotypes.
Materials and Methods. Patients, cell preparation, and flow cytometry.
Peripheral blood mononuclear cells (PBMCs) were obtained by
density centrifugation using Ficoll–Hypaque (Amersham Phar-
macia) and cryopreserved in RPMI medium 1640 supplemented
with 40%FCS and 10%DMSO (1 107 to 2 107 cells per vial).
For peptide stimulation experiments, CD8 T lymphocytes were
positively selected from PBMCs using anti-CD8-coated mag-
netic microbeads (Miltenyi Biotech), resulting in more than 90%
CD3CD8 lymphocytes. Cells from the CD8neg fraction were
irradiated (3,000 rad) and used as autologous antigen-presenting
cells (APCs). CD8pos-enriched lymphocytes (1  106 per well)
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were stimulated with the NY-ESO-1 analog peptide (1 M) and
irradiated autologous APCs in 2 ml of RPMI medium 1640
containing 8% of human serum, 10 units/ml human recombinant
IL-2 (hrIL-2; a gift from GlaxoSmithKline), and hrIL-7 (10
ng/ml; R&D Systems). A second round of peptide-specific
stimulation was performed after 15 days, and cells were cultured
for 15 additional days before HLA-A2/NY-ESO-1 multimer
analysis. Synthesis of phycoerythrin (PE)- or allophycocyanin-
labeled HLA-A*0201/peptide multimers was prepared as de-
scribed in ref. 11 with NY-ESO-1 analog peptide 157–165 C165A
(SLLMWITQA). Three-color stains were done with PE- or
allophycocyanin-labeled HLA-A2/peptide multimers, FITC-
conjugated anti-CD8 (Becton Dickinson), and PE-conjugated
anti-TCR BV1, BV8, and BV13 (Beckman Coulter). Cells were
first incubated with PE- or allophycocyanin-labeled multimers
for 30 min at 4°C in PBS, 0.2% BSA, 50 M EDTA, and then
with appropriate antibodies (30 min, 4°C). Cells were washed
once in the same buffer and immediately analyzed on a BD
Vantage flow cytometer by using CellQuest software (Becton
Dickinson).
Generation of T cell clones and functional cytolytic assays. Multimerpos
CD8pos T cells were sorted in a FACSVantage SE machine
(Becton Dickinson), cloned by limiting dilution, and expanded in
RPMI medium 1640 supplemented with 8% human serum (HS),
150 units/ml recombinant human IL-2 (rIL-2; a gift from Gl-
axoSmithKline), 1 g/ml phytohemagglutinin (PHA; Sodiag),
and 1 106/ml irradiated allogeneic PBMC (3,000 rad) as feeder
cells. A2/NY-ESO-1-multimer T cell clones were expanded by
periodic (every 15 days) restimulation in 24-well plates with
PHA, irradiated feeder cells, and hrIL-2.
The functional avidity of antigen recognition was analyzed for
in vitro generated T cell clones, isolated from patients LAU 50
and LAU 155, and bearing molecularly defined  TCR clono-
types. Antigen recognition was assessed in a 4-h 51Cr release
assay by using radioactively labeled T2 target cells (1,000 cells
per well; HLA-A2/TAP/) pulsed with serial dilutions of the
natural peptide residues 157–165 (SLLMWITQC) and the an-
alog peptide with a C to A substitution at peptide position 9 for
improved anchoring to HLA-A*0201 (12) before the addition of
the different T cell clonotypes (100,000 cells per well). Unless
otherwise specified, NY-ESO-1 peptides were preincubated for
1 h at room temperature with the disulfide-reducing agent Tris
[2-carboxyethyl] phosphine (TCEP; 2 mM, Pierce Biotechnol-
ogy) before being used to stimulate PBMCs or before functional
assays. In the latter case, TCEP was further added during the
assay at a final concentration of 500 M. The specific antigen
recognition lytic activity of the NY-ESO-1-specific T cell clono-
types was assessed against the melanoma cell lines Me 275 and
Me 290 (HLA-A2/NY-ESO-1) and NA8-MEL (HLA-A2/
NY-ESO-1). The percentage of specific lysis was calculated as
100  [(experimental  spontaneous release)/(total  sponta-
neous release)]. The relative antigenic activity of each peptide of
the set of NY-ESO-1157–165 single alanine-substituted peptide
variants toward different T cell clonotypes was calculated as the
[nM] 50% (EC50) of the parental NY-ESO-1157–165 nonapeptide
(SLLMWITQC) divided by the [nM] 50% of index peptide.
TCR BV and AV repertoire analysis. Briefly, cDNA generated from
NY-ESO-1pos T cell clones was subjected to individual PCRs by
using validated 5-sense fluorescent-labeled primers specific for
the V region of the -chain subfamilies 1, 8, and 13 (BV1, BV8,
and BV13), based on the nomenclature proposed by Arden et al.
(6), and one 3-antisense primer specific for the corresponding
C gene segment (13). PCR products were then run on an
automated sequencer in the presence of fluorescent size mark-
ers, and data analysis was performed with the Genescan analysis
software (Applied Biosystems). We then subjected the cDNA of
the TCR BV-identified NY-ESO-1-specific T cell clones to
individual PCRs by using a set of validated 5-sense primers
specific for 33 V region of the -chain (AV) subfamilies and one
3-antisense primer specific for the corresponding C gene seg-
ment (7). TCR AV-AC and BV-BC PCR products were directly
purified and sequenced (Fasteris).
Two distinct sets of primers (Metabion) specific for the CDR3
region of each identified BV1, BV8, and BV13 T cell clonotype
from patient LAU 50 were validated and used for clonotyping
PCR as described in ref. 8, (i) CDR3 clonotype forward and C
reverse, and (ii) BV subfamilies (BV1, BV8, or BV13) forward
and CDR3 clonotype reverse as follows: BV1 clonotype 1,
5-AGCGTAACAGGGACAGGGG-3 and rev-5-GCCCCCT-
GTCCCTGTTACG-3; BV1 clonotype 2, 5-GTAGATG-
GAAG CAATCAGCC-3 and rev-5-AAAATGCTGGGGCT-
GATTGC-3; BV8 clonotype 1, 5-ACTTCTGTGCCAGC-
CAACAG-3 and rev-5-AAAGCTTCAGTACCCCCCTG-3;
BV8 clonotype 2, 5-ACTTCTGTGCCAGCAGTCTC-3 and
rev-5-AAGCTTCAGTC CCCCCGAGA-3; BV8 clonotype 3,
5-GTTTGGGGGGCAATGAGCAG-3 and rev-5-GAACT-
GCTCATTGCCCCCCA-3; BV13 clonotype 1, 5-GAA-
CAGGGTTGGA CGGCTAC-3 and rev-5-GTAGCCGTC-
CAACCCTGTTC-3; BV13 clonotype 2, 5-AGTTACG-
TAGGGGGGAAGG-3 and rev-5-AGCCTTCCCCCC-
TACGTAA-3; and BV13 clonotype 3, 5-GACACTATAAT-
TCACCCCTCC-3 and rev-5-GGAGGGGTGAATTATAGT-
GTC-3.
Binding free energy calculations.To calculate the binding free energy
contributions of each residue of the NY-ESO-1 peptide to the
TCR–pMHC association, we chose the TCR BV13 clonotype 1
from LAU 155 and used the atomic coordinates of the highly
related TCR AV23-BV13 (1G4) bound to NY-ESO-1157–165/
HLA-A*0201, retrieved from the Protein Data Bank (PDB ID
code 2BNR) (14). Four TCR residues were mutated first, to
generate a 3D model of the TCR BV13 clonotype 1 from LAU
155 (see Fig. 4 of the main text); Thr-95 and Ser-96 of the
CDR3 were replaced by Gln and Thr, respectively, and the
Asn-97 and Thr-98 of the CDR3 were replaced by Ala. The in
silico amino acid substitutions were introduced into the refer-
ence TCR atomic coordinates by means of the Molecular
Mechanics–Generalized Born Surface Area (15, 16) (MM-
GBSA) approach for binding free energy estimation and de-
composition. This method was used previously on a TCR-pMHC
system and successfully reproduced the results of an experimen-
tal alanine scanning (16) as well as allowed a straightforward
decomposition of the binding free energy into backbone and
side-chain contributions for each residue as detailed in ref. 16.
The averaged binding free energy contributions were calculated
for all residues. All calculations were performed by using the
CHARMM package (version c31b1) (17) and the CHARMM22
all-atoms force field (18). Contributions were averaged over a
state of the art 1-ns MD simulation in explicit solvent, by using
periodic boundary conditions and at constant pressure (1 atm)
and temperature (300 K).
Computational TCR modeling. Homology models of the variable
domain of the TCR bound to the SLLMWITQC peptide pre-
sented by HLA-A*0201 were built by using Modeler 6v2 (19),
based on the 2BNR complex and other crystal structures of TCR
from the Protein Data Bank. The 2BNR complex (14) was used
as a structural template for TCR and pMHC homology model-
ing. From the available experimental structures of TCR or
TCR–pMHC class I complexes, we selected the variable domains
of 11 TCR (V and V) as additional templates for the
homology modeling: 1ao7, 1bd2, 1fo0, 1g6r, 1kb5, 1kj2, 1lp9,
1mi5, 1nfd, 1oga, and 2ckb. Lower-resolution redundant struc-
tures were excluded. Three unbound TCR V (1b88, 1i9e, and
1h5b) and two unbound TCRV (1bec and 1ktk) structures were
added to the templates list. The TCRV structure 1934.4 was
also used (20). Because the only complete TCR–pMHC template
used was 2BNR, it is expected that the resulting models will have
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a similar overall TCR orientation over pMHC, although small
adjustments are possible. Once a homology model was obtained,
each CDR loop was refined individually, while the rest of the
complex, including the other CDR loops, remained unchanged.
The loop modeling algorithm consists of a cycle of molecular
dynamics simulations, combined with simulated annealing, op-
timizing the Modeler pseudoenergy function. Whenever possi-
ble, this function was improved by adding restraints specific to
the nature of the CDR loop, derived from the rules given by
Al-Lazikani et al. (21), where the identification of key amino
acids defines limitations to the conformation space accessible to
a CDR loop. The loops were refined one by one, in the following
order, CDR2, CDR1, CDR2, CDR1, then both CDR3
and  were modeled at the same time. From each model that was
obtained, we used CHARMM to calculate and decompose the
binding free energy according to the MM-GBSA approach (15,
16), except that the quantities were not averaged along an MD
simulation trajectory but calculated from the single structural
model because of computing limitations. A 4 kcal/mol cutoff was
applied to all residue contributions. Thus, all contributions that
were larger than 4 kcal/mol or lower than 4 kcal/mol were set
to 4 kcal/mol and 4 kcal/mol, respectively. This was done
because values were calculated from a single structure and not
averaged along a molecular dynamics simulation trajectory,
leading to possible overestimation of favorable or unfavorable
contributions. This cutoff was based on the maximum values that
are usually observed by experimental alanine scanning (22). To
assess the impact of the cutoff on the results, different values
ranging from 3 kcal/mol to 6 kcal/mol were tested. No
significant change in the calculated G,bind and G,bind con-
tributions were found, illustrating the robustness of the results
(data not shown). Of note, because of its particularly long
CDR3 and , the BV13 clono1 from patient LAU 198 can be
considered as an outlier and was removed from the calculations.
In particular, the last step of the loop-modeling algorithm needs
to estimate theoretically the conformation of a 23-aa loop, which
is out of reach for the method.
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Fig. S1. TCR-BV usage of naturally occurring HLA-A*0201/NY-ESO-1157–165 multimer T cells in peptide-stimulated PBMCs from melanoma patients. Flow
cytometry analysis of CD8multimer T lymphocytes (R1) by using TCR BV1-, BV8-, and BV13-specific mAbs was performed. Data are shown as the percentage
of BVx-expressing cells among CD8 multimer T cells. Of note, only patients exhibiting the highest frequencies of NY-ESO-1-specific T cells are depicted (LAU
50, LAU 155, LAU 156, and LAU 198).
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Fig. S2. Characterization of dominant T cell clones by clonotypic PCR and sequencing. (A) Unique primers corresponding to the CDR3 gene segment of each
identified TCR clonotype were designed and validated (see SIMaterials andMethods). Two distinct sets of primers were used: (i) BVx forward–clonotype reverse
(BVclono-Rev) and (ii) clonotype forward (BVclono-Fwd)–C Reverse. (B–D) Clonotypic BV1 (B), BV8 (C), and BV13 (D) PCRs were performed on in vitro generated
NY-ESO-1-specific T cell clones from patient LAU 50. The size for each amplified BV-CDR3-BC product is indicated (in base pairs). PCRs performed on distinct T
cell clones bearing the same TCR clonotype are also depicted. () refers to low PCR expression levels. (E) The proportion (in percentage) of PCRs generating/
signals (positive PCR products with both BVclono-Fwd and BVclono-Rev sets of primers), / (positive PCR products with BVclono-Fwd only), and / signals
(positive PCR products with BVclono-Rev only). The percentage of BV1, BV8, and BV13 clonotypes confirmed by sequencing is depicted within each column and
highlighted as gray bars. Of note, 64% of ‘‘true’’ BV8 T cell clonotypes gave a / PCR signal (false negatives). Conversely, 25% of / PCR signals were not
specific for the correct BV8 clonotype sequence (false positives). n represents the number of single T cell clones analyzed.
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Fig. S3. Melanoma cell killing by T cell clones from patient LAU 50. (A) Tumor reactivity for the autologous melanoma cell lines Me 275 (A2/NY-ESO-1) and
the allogeneic lines Me 290 (A2/NY-ESO-1) and NA8 (A2/NY-ESO-1) in the absence or presence of NY-ESO-1157–165 analog peptide (1M) at an effector:target
ratio of 30:1. Representative examples of percentage of specific lysis by BV1, BV8, and BV13 clonotypes 1 and 2 are depicted. (B) Complete set of data (n  82
clones) representing the specific lysis of HLA-A2 tumor cells expressing NY-ESO-1 in the absence of peptide (30:1; effector:target ratio). Each data point
represents the result of an individual clone. Mean  SD values (in percentage) are shown.
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Fig. S4. Assessment of NY-ESO-1-peptide recognition of NY-ESO-1-specific T cell clones derived from patient LAU 155. (A) Representative examples of
percentage of specific lysis by BV1, BV8, and BV13 clonotypes are depicted. The data show lysis of T2 cells loaded with varying concentrations of either native
NY-ESO-1 peptide (open symbols) or its C165A substituted peptide analog (filled symbols). (B) Complete set of data (n  17) representing the peptide
concentration (either native or analog) required for 50% of maximum lysis. Each point represents the result of an individual clone. Mean SD values (nanomolar)
are shown.
Derre´ et al. www.pnas.org/cgi/content/short/0807954105 7 of 7
